C12Y 403/02001
Argininosuccinate lyase
Official title: Argininosuccinate lyase (4.3.2.1)
C12Y403/02001 (Argininosuccinate lyase) appears on 21 US grants and 54 published applications in this corpus.
Search patents in C12Y- Granted patents
- 21
- Published applications
- 54
- Assignees
- 11
- Inventors
- 43
- Latest grant
- 20 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 26 |
| 2015 | 9 | 1 |
| 2016 | 2 | 2 |
| 2017 | 2 | 2 |
| 2018 | 0 | 3 |
| 2019 | 2 | 2 |
| 2020 | 4 | 1 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 1 | 2 |
| 2025 | 0 | 4 |
| 2026 | 0 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for the fermentative production of guanidinoacetic acid20 Aug 2024US 12,065,677 B2Evonik Operations GmbH
- Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins31 Jan 2023US 11,564,998 B2ModernaTX, Inc.
- Messenger UNA molecules and uses thereof27 Oct 2020US 10,815,463 B2Arcturus Therapeutics, Inc.
- Modified Polynucleotides for the production of biologics and proteins associated with human disease15 Sep 2020US 10,772,975 B2ModernaTX, Inc.
- In vivo production of proteins10 Mar 2020US 10,583,203 B2ModernaTX, Inc.
- Method for the fermentative production of guanidinoacetic acid using a microorganism comprising a heterologous l-threonine 3-dehydrogenase gene (tdh) and a glycine c-acetyltransferase gene (kbl)6 Aug 2026US 2026/0226404 A1Evonik Operations GmbH
- Fermentative production guanidinoacetic acid (gaa) from serine by attenuating l serine ammonia lyase activity in microorganisms30 Jul 2026US 2026/0218253 A1Evonik Operations GmbH
- New ethylenediamine-n,n'-disuccinic acid (edds) synthases23 Jul 2026US 2026/0209807 A1BASF SE
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Lyase (ASL)2 Jul 2026US 2026/0185086 A1Korro Bio, Inc.
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
Most cited
By later US patents
- Modified polynucleotides for the production of biologics and proteins associated with human disease196US 8,999,380 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating protein deficiency194US 9,061,059 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1124US 9,095,552 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides encoding citeD4124US 9,114,113 B2Moderna Therapeutics, Inc. · 2015
- Modified polynucleotides for treating galactosylceramidase protein deficiency121US 9,089,604 B2Moderna Therapeutics, Inc. · 2015